Preview

Российский кардиологический журнал

Расширенный поиск

АНТАГОНИСТЫ КАЛЬЦИЯ В ЛЕЧЕНИИ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ: ОСОБЕННОСТИ ЛЕРКАНИДИПИНА

https://doi.org/10.15829/1560-4071-2015-2-110-114

Полный текст:

Аннотация

Лерканидипин — это дигидропиридиновый антагонист кальция 3 поколения, характеризующий высокой вазоселективностью, длительным действием и хорошей антигипертензивной эффективностью. В обзоре рассмотрены основные особенности фармакокинетики и механизма действия препарата. Показано, что лечение лерканидипином характеризуется нефропротективным действием, уменьшает гипертрофию левого желудочка, улучшает эластические свойства сосудов и снижает центральное давление. Симпатическая активация при применении лерканидипина практически отсутствует, что обеспечивает его хорошую переносимость и приверженность больных к лечению.

Об авторе

Л. О. Минушкина
ФГБУ Учебно-научный медицинский центр УД Президента РФ, Москва
Россия

профессор кафедры терапии, кардиологии и функциональной диагностики



Список литературы

1. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Journal of Hypertension 2013, 31: 1281-57.

2. Meredith PA. Lercanidipine: a novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity. Expert Opin Investig Drugs. 1999 Jul; 8(7): 1043-62.

3. Reddy GS, Nayak UY, Deshpande PB, Mutalik S . Gastroretentive Pulsatile Release Tablets of Lercanidipine HCl: Development, Statistical Optimization, and In Vitro and In Vivo Evaluation. ScientificWorldJournal. 2014; 2014: 421931.

4. Brixius K, Gross T, Tossios P, et al. Increased vascular selectivity and prolonged pharmacological efficacy of the L-type Ca2+ channel antagonist lercanidipine in human cardiovascular tissue. Clin Exp Pharmacol Physiol. 2005 Sep; 32(9): 708-13.

5. Grassi G, Seravalle G, Turri C, et al. Short-versus long-term effects of different dihydropyridines on sympathetic and baroreflex function in hypertension. Hypertension. 2003 Mar; 41(3): 558-62.

6. Vasigar P, Batmanabane M. Anti-inflammatoryactivity of calciumchannel blocker lercanidipine hydrochloride. J Pharmacol Pharmacother. 2013 Oct; 4(4): 238-42.

7. Farah R, Khamisy-Farah R, Shurtz-Swirski R. C alcium channel blocker effect on insulin resistance and inflammatory markers in essential hypertension patients. Int Angiol. 2013 Feb; 32(1): 85-93.

8. Mackenzie IS, McEniery CM, Dhakam Z, et al. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension. 2009 Aug; 54(2): 409-13.

9. Martinez ML, Lopes LF, Coelho EB, et al. Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J Cardiovasc Pharmacol. 2006 Jan; 47(1): 117-22.

10. Poncelet P, Ribstein J, Goullard L, et al. Efficacy and acceptability of lercanidipine are not age dependent in patients with essential hypertension: the AGATE study Ann Cardiol Angeiol (Paris). 2004 Jun; 53(3):123-30.

11. Wu Y, Xu M, Wang H, et al. Lercanidipine hydrochloride versus felodipine sustained-release for mild-to-moderate hypertension: a multi-center, randomized clinical trial. Curr Med Res Opin. 2015 Jan; 31(1): 171-6.

12. Thuc Sinh C, Van Minh H, Van Huy T . E ffects of lercanidipine versus amlodipine in hypertensive patients with cerebral ischemic stroke. Curr Med Res Opin. 2015 Jan; 31(1): 163-70.

13. Millar-Craig M, Shaffu B, Greenough A, et al. Lercanidipine vs lacidipine in isolated systolic hypertension. J Hum Hypertens. 2003 Nov; 17(11): 799-806.

14. McClellan KJ, Jarvis B . Lercanidipine: a review of its use in hypertension. Drugs. 2000 Nov; 60(5): 1123-40.

15. Cicero AF, Gerocarni B, Rosticci M, Borghi C . B lood pressure and metabolic effect of a combination of lercanidipine with different antihypertensive drugs in clinical practice. Clin Exp Hypertens. 2012; 34(2): 113-7.

16. Yang Z. E fficacy and safety evaluation of perindopril-lercanidipine combined therapy in patients with mild essential hypertension. Curr Med Res Opin. 2015 Jan; 31(1): 183-6.

17. De Ciuceis C, Salvetti M, Rossini C, et al. Effect of antihypertensive treatment on microvascular structure, central blood pressure and oxidative stress in patients with mild essential hypertension. J Hypertens. 2014 Mar; 32(3): 565-74.

18. Dalla Vestra M, Pozza G, Mosca A, et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Diabetes Nutr Metab. 2004 Oct; 17(5): 259-266.

19. Peng M, Jiang XJ, Dong H, et al. Can lercanidipine improve renal function in patients with atherosclerotic renal artery stenosis undergoing renal artery intervention? Curr Med Res Opin. 2015 Jan; 31(1): 177-82.

20. Robles NR, Pastor L, Manjón M, et al. Lercanidipine in diabetic patients with renal failure. Nefrologia. 2004; 24(4): 338-43.

21. Topal C, Erkoc R, Sayarlioglu H, Comparative effects of carvedilol and lercanidipine on ultrafiltration and solute transport in CAPD patients. . Ren Fail. 2009; 31(6): 446-51.

22. Campo C, Saavedra J, Segura J, et al. Correlations of smoothness index and trough-to-peak ratio with left ventricular mass index changes induced by lercanidipine in hypertensive patients. A pilot trial. Minerva Med. 2005 Oct; 96(5): 365-71.

23. Mackenzie IS, McEniery CM, Dhakam Z, et al. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension. 2009 Aug; 54(2): 409-13.

24. Grassi G, Quarti-Trevano F, Scopelliti F, et al. Effects of long-term lercanidipine or hydrochlorothiazide administration on hypertension-related vascular structural changes. Blood Press. 2006; 15(5): 268-74.

25. Tisaire-Sánchez J, Roma J, Camacho-Azcargorta I, et al. Assessment of cognitive function in patients with essential hypertension treated with lercanidipine. Vasc Health Risk Manag. 2006; 2(4): 491-87.

26. Barrios V, Escobar C, Navarro A, et al. Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: The LAURA study. Int J Clin Pract. 2006 Nov; 60(11): 1364-70.

27. Cherubini A, Fabris F, Ferrari E, et al. Comparative effects of lercanidipine, lacidipine, and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) study. Arch Gerontol Geriatr. 2003 Nov-Dec; 37(3): 203-12.

28. Romito R, Pansini MI, Perticone F, et a. Comparative effect of lercanidipine, felodipine, and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercanidipine in Adults (LEAD) Study. J Clin Hypertens (Greenwich). 2003 Jul-Aug; 5(4): 249-53.

29. Sansanayudh N, Wongwiwatthananukit S, Veerayuthvilai S . C omparison of changes of body water measured by using bioelectrical impedance analysis between lercanidipine and amlodipine therapy in hypertensive outpatients. J Med Assoc Thai. 2010 Nov; 93 Suppl 6: S84-92.

30. Lund-Johansen P, Stranden E, Helberg S, et al. Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine. J Hypertens. 2003 May; 21(5): 1003-10.

31. Elliott HL, Meredith PA. Thrapeutic equivalence in the treatment of hypertension: Can lercanidipine and nifedipine GITS be considered to be interchangeable? World J Cardiol. 2014 Jun 26; 6(6): 507-13.

32. Makarounas-Kirchmann K, Glover-Koudounas S, Ferrari P . Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers. Clin Ther. 2009 Aug; 31(8): 1652-63.

33. Prandin MG, Cicero AF, Veronesi M, et al. Persistence on treatment and blood pressure control with different first-line antihypertensive treatments: a prospective evaluation. Clin Exp Hypertens. 2007 Nov; 29(8): 553-62.


Для цитирования:


Минушкина Л.О. АНТАГОНИСТЫ КАЛЬЦИЯ В ЛЕЧЕНИИ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ: ОСОБЕННОСТИ ЛЕРКАНИДИПИНА. Российский кардиологический журнал. 2015;(2):110-114. https://doi.org/10.15829/1560-4071-2015-2-110-114

For citation:


Minushkina I.O. CALCIUM ANTAGONISTS IN ARTERIAL HYPERTENSION TREATMENT: SPECIFICS OF LERCANIDIPINE. Russian Journal of Cardiology. 2015;(2):110-114. (In Russ.) https://doi.org/10.15829/1560-4071-2015-2-110-114

Просмотров: 321


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1560-4071 (Print)
ISSN 2618-7620 (Online)